ICAM1 and cerebral malaria: Importantly, we demonstrated that the MMP inhibitor batimastat can prevent glycocalyx shedding67 and the temperature-dependent increase in binding to EPCR and ICAM-1, suggesting potential therapeutic benefit, in agreement with previous mouse experimental cerebral malaria studies showing delayed mortality68.